StockSelector.com
  Research, Select, & Monitor Monday, December 11, 2017 9:58:20 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Johnson & Johnson$140.15($.44)(.31%)

  Quote | Ranking | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

 Johnson & Johnson Reports 2017 First-Quarter Results:
   Tuesday, April 18, 2017 6:40:00 AM ET

Johnson & Johnson (JNJ ) today announced sales of $17.8 billion for the first quarter of 2017, an increase of 1.6% as compared to the first quarter of 2016. Operational sales results increased 2.0% and the negative impact of currency was 0.4%. Domestic sales increased 0.6%. International sales increased 2.8%, reflecting operational growth of 3.6% and a negative currency impact of 0.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.2%, domestic sales decreased 0.7% and international sales increased 3.4%.*

https://mma.prnewswire.com/media/403394/Johnson_and_Johnson_Logo.jpg

Net earnings and diluted earnings per share for the first quarter of 2017 were $4.4 billion and $1.61, respectively. First-quarter 2017 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.4 billion. First-quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.2 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $5.0 billion and adjusted diluted earnings per share were $1.83, representing increases of 3.8% and 5.8%, respectively, as compared to the same period in 2016.* On an operational basis, adjusted diluted earnings per share also increased 7.5%.* A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"Johnson & Johnson’s first-quarter results are in line with our expectations and we are confident we will achieve the full-year financial guidance we established at the beginning of the year," said Alex Gorsky, Chairman and Chief Executive Officer. "The pending acquisition of Actelion demonstrates our ongoing commitment to bringing innovation to patients with significant unmet needs, and provides a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We look forward to the associates from Actelion joining the Johnson & Johnson Family of Companies."

The Company is now including the estimated impact of the Actelion transaction in its financial guidance. As such, the Company increased its sales guidance for the full-year 2017 to $75.4 billion to $76.1 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2017 to $7.00 - $7.15 per share.*

Worldwide Consumer sales of $3.2 billion for the first quarter 2017 represented an increase of 1.0% versus the prior year, consisting of an operational increase of 0.8% and a positive impact from currency of 0.2%. Domestic sales increased 4.1%; international sales decreased 1.3%, which reflected an operational decrease of 1.6% and a positive currency impact of 0.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales decreased 2.3%, domestic sales decreased 2.9% and international sales decreased 1.9%*.

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were negatively impacted by LISTERINE? oral care products, baby care products, and wound care products, partially offset by growth in over-the-counter products, including domestic TYLENOL? analgesics.

Worldwide Pharmaceutical sales of $8.2 billion for the first quarter 2017 represented an increase of 0.8% versus the prior year with an operational increase of 1.4% and a negative impact from currency of 0.6%. Domestic sales decreased 1.3%; international sales increased 4.1%, which reflected an operational increase of 5.6% and a negative currency impact of 1.5%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 2.2%, domestic sales decreased 0.4% and international sales increased 6.1%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by new products and the strength of core products. Strong growth in new products include DARZALEX? (daratumumab), for the treatment of patients with multiple myeloma and IMBRUVICA? (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. Additional contributors to operational sales growth included STELARA? (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, and INVEGA? SUSTENNA?/XEPLION?/TRINZA? (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults. Sales growth was negatively impacted by a positive adjustment of rebate accruals in the first quarter of 2016, which did not occur to the same degree in the first quarter of 2017.

During the quarter, the Company announced a definitive agreement to acquire Actelion Ltd., a leading biopharmaceutical company, for approximately $30 billion. The public tender offer for Actelion has been declared successful based on the number of shares tendered and regulatory approval has been obtained in six of seven jurisdictions in which the company filed for such approval, with antitrust approval from the European Commission pending. The transaction is expected to close in the second quarter of 2017, subject to the satisfaction of remaining closing conditions.

Also in the quarter, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending broadening the existing marketing authorization for DARZALEX? (daratumumab) for use in combination with lenalidomide and dexamethasone; or bortezomib and dexamethasone, for the treatment of multiple myeloma in patients who have received at least one prior therapy. A supplemental New Drug Application was submitted to the U.S. Food and Drug Administration for IMBRUVICA? (ibrutinib) for the treatment of chronic Graft-Versus-Host Disease after failure of one or more lines of systemic therapy.

In April, subsequent to the quarter, a marketing authorization application was submitted to the European Medicines Agency for ZYTIGA? (abiraterone acetate) to expand the existing indication to include treatment of men with newly diagnosed high-risk metastatic hormone sensitive prostate cancer.

Worldwide Medical Devices sales of $6.3 billion for the first quarter 2017 represented an increase of 3.0% versus the prior year consisting of an operational increase of 3.4% and a negative currency impact of 0.4%. Domestic sales increased 2.2%; international sales increased 3.8%, which reflected an operational increase of 4.7% and a negative currency impact of 0.9%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.7%, domestic sales decreased 0.2% and international sales increased 3.7%.*

Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by electrophysiology products in the Cardiovascular business; ACUVUE? contact lenses in the Vision Care business and endocutters in the Advanced Surgery business, partially offset by declines in the Diabetes Care business.

During the quarter, the company completed the acquisition of Abbott Medical Optics, a wholly-owned subsidiary of Abbott and global leader in ophthalmic surgery, for approximately $4.3 billion.

Additionally, the acquisitions of Megadyne Medical Products, Inc., a privately held medical device company that develops, manufactures and markets electrosurgical tools, and Torax Medical Inc., a privately held medical device company that manufactures and markets the LINX(TM) Reflux Management System for the surgical treatment of gastroesophageal reflux disease, were completed.

In April, subsequent to the quarter, the acquisition of Neuravi Limited, a privately held medical device company that develops and markets medical devices for neurointerventional therapy, was completed.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings, adjusted diluted earnings per share and operational adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company’s website at www.investor.jnj.com. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson’s results computed in accordance with GAAP.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the company’s website at www.investor.jnj.com.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; market conditions and the possibility that the on-going share repurchase program may be delayed, suspended or discontinued; the impact of business combinations and divestitures, including the planned acquisition of Actelion Ltd.; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)    FIRST QUARTER
                                                       Percent Change
                                    2017       2016    Total    Operations  Currency
Sales to customers by
segment of business
Consumer
U.S.                                $   1,414  1,358   4.1   %  4.1         -
International                       1,814      1,837   (1.3)    (1.6)       0.3
                                    3,228      3,195   1.0      0.8         0.2
Pharmaceutical
U.S.                                4,872      4,937   (1.3)    (1.3)       -
International                       3,373      3,241   4.1      5.6         (1.5)
                                    8,245      8,178   0.8      1.4         (0.6)
Medical Devices
U.S.                                3,092      3,026   2.2      2.2         -
International                       3,201      3,083   3.8      4.7         (0.9)
                                    6,293      6,109   3.0      3.4         (0.4)
U.S.                                9,378      9,321   0.6      0.6         -
International                       8,388      8,161   2.8      3.6         (0.8)
Worldwide                           $ 17,766   17,482  1.6   %  2.0         (0.4)
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)    FIRST QUARTER
                                                       Percent Change
                                    2017       2016    Total    Operations  Currency
Sales to customers by
geographic area
U.S.                                $   9,378  9,321   0.6   %  0.6         -
Europe                              3,858      3,847   0.3      4.2         (3.9)
Western Hemisphere excluding U.S.   1,454      1,331   9.2      2.5         6.7
Asia-Pacific, Africa                3,076      2,983   3.1      3.4         (0.3)
International                       8,388      8,161   2.8      3.6         (0.8)
Worldwide                           $ 17,766   17,482  1.6   %  2.0         (0.4)
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)                 FIRST QUARTER
                                                                  2017                      2016                      Percent
                                                                                  Percent                   Percent   Increase
                                                                  Amount          to Sales  Amount          to Sales  (Decrease)
Sales to customers                                                $    17,766     100.0     $    17,482     100.0     1.6
Cost of products sold                                             5,386           30.3      5,329           30.5      1.1
Selling, marketing and administrative expenses                    4,737           26.6      4,688           26.8      1.0
Research and development expense                                  2,060           11.6      2,013           11.5      2.3
Interest (income) expense, net                                    83              0.5       77              0.4
Other (income) expense, net                                       (160)           (0.9)     (39)            (0.2)
Restructuring                                                     85              0.5       120             0.7
Earnings before provision for taxes on income                     5,575           31.4      5,294           30.3      5.3
Provision for taxes on income                                     1,153           6.5       837             4.8       37.8
Net earnings                                                      4,422           24.9      4,457           25.5      (0.8)
Net earnings per share (Diluted)                                  $        1.61             $        1.59             1.3
Average shares outstanding (Diluted)                              2,754.5                   2,803.8
Effective tax rate                                                20.7          %           15.8          %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income                     $      6,103    34.4      $      5,801    33.2      5.2
Net earnings                                                      $      5,038    28.4      $      4,854    27.8      3.8
Net earnings per share (Diluted)                                  $        1.83             $        1.73             5.8
Effective tax rate                                                17.5          %           16.3          %
(1)See Reconciliation of Non-GAAP Financial Measures.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
                                                                                                  First Quarter                                     % Incr. /
(Dollars in Millions Except Per Share Data)                                                       2017                     2016                     (Decr.)
Earnings before provision for taxes on income - as reported                                       $      5,575             5,294                    5.3                     %
Intangible asset amortization expense                                                             329                      282
Restructuring/Other (1)                                                                           161                      137
Litigation expense, net                                                                           -                        66
AMO acquisition related cost                                                                      38                       -
Other                                                                                             -                        22
Earnings before provision for taxes on income - as adjusted                                       $      6,103             5,801                    5.2                     %
Net Earnings - as reported                                                                        $      4,422             4,457                    (0.8)                   %
Intangible asset amortization expense                                                             244                      205
Restructuring/Other                                                                               121                      120
Litigation expense, net                                                                           -                        56
AMO acquisition related cost                                                                      251                      -
Other                                                                                             -                        16
Net Earnings - as adjusted                                                                        $      5,038             4,854                    3.8                     %
Diluted Net Earnings per share - as reported                                                      $        1.61            1.59                     1.3                     %
Intangible asset amortization expense                                                             0.09                     0.07
Restructuring/Other                                                                               0.04                     0.04
Litigation expense, net                                                                           -                        0.02
AMO acquisition related cost                                                                      0.09                     -
Other                                                                                             -                        0.01
Diluted Net Earnings per share - as adjusted                                                      $        1.83            1.73                     5.8                     %
Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates                           1.77
Impact of currency at 2016 foreign currency exchange rates                                        0.03                     (0.04)
Operational Diluted Net Earnings per share - as adjusted at 2016 foreign currency exchange rates  $        1.86            1.73                     7.5                     %
(1) Includes $4M recorded in cost of products sold and $72M recorded in other (income) expense in the first quarter 2017 and $17M recorded in cost of products sold in the first quarter 2016.
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Operational Sales Growth Excluding Acquisitions and Divestitures
FIRST QUARTER 2017 ACTUAL vs. 2016 ACTUAL
Segments
                                                                     Consumer  Pharmaceutical  Medical Devices  Total
                                                                     Operational %(1)
WW As Reported:                                                      0.8%      1.4%            3.4%             2.0%
U.S.                                                                 4.1%      (1.3)%          2.2%             0.6%
International                                                        (1.6)%    5.6%            4.7%             3.6%
Beauty
Vogue                                                                (3.0)                                      (0.6)
U.S.                                                                 (6.3)                                      (0.9)
International                                                        (0.7)                                      (0.1)
Other Neuroscience
Controlled Substance Raw Material and API Business                             0.8                              0.4
U.S.                                                                           0.9                              0.5
International                                                                  0.5                              0.2
Diagnostics
Ortho-Clinical Diagnostics                                                                     0.5              0.2
U.S.                                                                                           0.0              0.0
International                                                                                  1.0              0.4
Vision Care
Abbott Medical Optics                                                                          (2.0)            (0.7)
U.S.                                                                                           (1.7)            (0.6)
International                                                                                  (2.3)            (0.9)
All Other Acquisitions and Divestitures                              (0.1)                     (0.2)            (0.1)
U.S.                                                                 (0.7)                     (0.7)            (0.3)
International                                                        0.4                       0.3              0.2
WW Ops excluding Acquisitions and Divestitures                       (2.3)%    2.2%            1.7%             1.2%
U.S.                                                                 (2.9)%    (0.4)%          (0.2)%           (0.7)%
International                                                        (1.9)%    6.1%            3.7%             3.4%
(1)Operational growth excludes the effect of translational currency
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                % Change
                                          2017            2016  Reported Operational (1) Currency
CONSUMER SEGMENT (2) (3)
BABY CARE
US                                        $          113  121   -6.6%    -6.6%           -
Intl                                      342             362   -5.5%    -6.1%           0.6%
WW                                        455             483   -5.8%    -6.3%           0.5%
BEAUTY
US                                        567             484   17.1%    17.1%           -
Intl                                      414             395   4.8%     5.0%            -0.2%
WW                                        981             879   11.6%    11.7%           -0.1%
ORAL CARE
US                                        156             170   -8.2%    -8.2%           -
Intl                                      206             215   -4.2%    -4.5%           0.3%
WW                                        362             385   -6.0%    -6.2%           0.2%
OTC
US                                        477             466   2.4%     2.4%            -
Intl                                      536             533   0.6%     0.7%            -0.1%
WW                                        1,013           999   1.4%     1.5%            -0.1%
WOMEN’S HEALTH
US                                        3               6     -50.0%   -50.0%          -
Intl                                      239             245   -2.4%    -4.2%           1.8%
WW                                        242             251   -3.6%    -5.3%           1.7%
WOUND CARE / OTHER
US                                        98              111   -11.7%   -11.7%          -
Intl                                      77              87    -11.5%   -12.3%          0.8%
WW                                        175             198   -11.6%   -11.9%          0.3%
TOTAL CONSUMER
US                                        1,414           1,358 4.1%     4.1%            -
Intl                                      1,814           1,837 -1.3%    -1.6%           0.3%
WW                                        $       3,228   3,195 1.0%     0.8%            0.2%
See footnotes at end of schedule
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                % Change
                                          2017            2016  Reported Operational (1) Currency
PHARMACEUTICAL SEGMENT (2) (3)
IMMUNOLOGY
US                                        $       2,123   2,171 -2.2%    -2.2%           -
Intl                                      807             739   9.2%     9.0%            0.2%
WW                                        2,930           2,910 0.7%     0.6%            0.1%
REMICADE
US                                        1,182           1,211 -2.4%    -2.4%           -
US Exports (4)                            165             233   -29.2%   -29.2%          -
Intl                                      325             335   -3.0%    -4.8%           1.8%
WW                                        1,672           1,779 -6.0%    -6.3%           0.3%
SIMPONI / SIMPONI ARIA
US                                        229             216   6.0%     6.0%            -
Intl                                      199             174   14.4%    13.4%           1.0%
WW                                        428             390   9.7%     9.2%            0.5%
STELARA
US                                        547             511   7.0%     7.0%            -
Intl                                      276             224   23.2%    26.1%           -2.9%
WW                                        823             735   12.0%    12.9%           -0.9%
OTHER IMMUNOLOGY
US                                        -               -     -        -               -
Intl                                      7               6     16.7%    12.1%           4.6%
WW                                        7               6     16.7%    12.1%           4.6%
INFECTIOUS DISEASES
US                                        326             358   -8.9%    -8.9%           -
Intl                                      423             418   1.2%     2.8%            -1.6%
WW                                        749             776   -3.5%    -2.6%           -0.9%
EDURANT / RILPIVIRINE
US                                        12              11    9.1%     9.1%            -
Intl                                      137             108   26.9%    30.4%           -3.5%
WW                                        149             119   25.2%    28.3%           -3.1%
PREZISTA / PREZCOBIX / REZOLSTA
US                                        259             277   -6.5%    -6.5%           -
Intl                                      171             175   -2.3%    0.2%            -2.5%
WW                                        430             452   -4.9%    -3.9%           -1.0%
OTHER INFECTIOUS DISEASES
US                                        55              70    -21.4%   -21.4%          -
Intl                                      115             135   -14.8%   -15.9%          1.1%
WW                                        170             205   -17.1%   -17.8%          0.7%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                % Change
                                          2017            2016  Reported Operational (1) Currency
NEUROSCIENCE
US                                        664             680   -2.4%    -2.4%           -
Intl                                      833             869   -4.1%    -2.9%           -1.2%
WW                                        1,497           1,549 -3.4%    -2.7%           -0.7%
CONCERTA / METHYLPHENIDATE
US                                        108             134   -19.4%   -19.4%          -
Intl                                      101             97    4.1%     4.2%            -0.1%
WW                                        209             231   -9.5%    -9.5%           0.0%
INVEGA SUSTENNA / XEPLION / TRINZA
US                                        372             305   22.0%    22.0%           -
Intl                                      232             208   11.5%    14.3%           -2.8%
WW                                        604             513   17.7%    18.8%           -1.1%
RISPERDAL CONSTA
US                                        95              95    0.0%     0.0%            -
Intl                                      112             136   -17.6%   -15.7%          -1.9%
WW                                        207             231   -10.4%   -9.3%           -1.1%
OTHER NEUROSCIENCE
US                                        89              146   -39.0%   -39.0%          -
Intl                                      388             428   -9.3%    -8.9%           -0.4%
WW                                        477             574   -16.9%   -16.6%          -0.3%
ONCOLOGY
US                                        664             549   20.9%    20.9%           -
Intl                                      930             805   15.5%    18.3%           -2.8%
WW                                        1,594           1,354 17.7%    19.3%           -1.6%
DARZALEX
US                                        201             101   99.0%    99.0%           -
Intl                                      54              -     *        *               0.0%
WW                                        255             101   *        *               0.0%
IMBRUVICA
US                                        190             132   43.9%    43.9%           -
Intl                                      219             129   69.8%    73.7%           -3.9%
WW                                        409             261   56.7%    58.6%           -1.9%
VELCADE
US                                        -               -     -        -               -
Intl                                      280             304   -7.9%    -5.0%           -2.9%
WW                                        280             304   -7.9%    -5.0%           -2.9%
ZYTIGA
US                                        233             272   -14.3%   -14.3%          -
Intl                                      290             286   1.4%     2.7%            -1.3%
WW                                        523             558   -6.3%    -5.6%           -0.7%
OTHER ONCOLOGY
US                                        40              44    -9.1%    -9.1%           -
Intl                                      87              86    1.2%     4.1%            -2.9%
WW                                        127             130   -2.3%    -0.4%           -1.9%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                % Change
                                          2017            2016  Reported Operational (1) Currency
CARDIOVASCULAR / METABOLISM / OTHER
US                                        1,095           1,179 -7.1%    -7.1%           -
Intl                                      380             410   -7.3%    -4.5%           -2.8%
WW                                        1,475           1,589 -7.2%    -6.5%           -0.7%
XARELTO
US                                        513             567   -9.5%    -9.5%           -
Intl                                      -               -     -        -               -
WW                                        513             567   -9.5%    -9.5%           -
INVOKANA / INVOKAMET
US                                        247             297   -16.8%   -16.8%          -
Intl                                      37              28    32.1%    32.8%           -0.7%
WW                                        284             325   -12.6%   -12.5%          -0.1%
PROCRIT / EPREX
US                                        169             183   -7.7%    -7.7%           -
Intl                                      78              91    -14.3%   -13.1%          -1.2%
WW                                                         247                     274             -9.9%           -9.5%           -0.4%
OTHER
US                                                         166                     132             25.8%           25.8%           -
Intl                                                       265                     291             -8.9%           -5.4%           -3.5%
WW                                                         431                     423             1.9%            4.3%            -2.4%
TOTAL PHARMACEUTICAL
US                                                         4,872                   4,937           -1.3%           -1.3%           -
Intl                                                       3,373                   3,241           4.1%            5.6%            -1.5%
WW                                                         $       8,245           8,178           0.8%            1.4%            -0.6%
See footnotes at end of schedule
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                                                   % Change
                                                           2017                    2016            Reported        Operational (1) Currency
MEDICAL DEVICES SEGMENT (2)
CARDIOVASCULAR
US                                                         $          259          231             12.1%           12.1%           -
Intl                                                       240                     212             13.2%           14.2%           -1.0%
WW                                                         499                     443             12.6%           13.1%           -0.5%
DIABETES CARE
US                                                         154                     180             -14.4%          -14.4%          -
Intl                                                       245                     249             -1.6%           -0.8%           -0.8%
WW                                                         399                     429             -7.0%           -6.5%           -0.5%
DIAGNOSTICS
US                                                         -                       -               -               -               -
Intl                                                       1                       28              **              **              **
WW                                                         1                       28              **              **              **
ORTHOPAEDICS
US                                                         1,379                   1,392           -0.9%           -0.9%           -
Intl                                                       946                     949             -0.3%           1.0%            -1.3%
WW                                                         2,325                   2,341           -0.7%           -0.2%           -0.5%
HIPS
US                                                         209                     203             3.0%            3.0%            -
Intl                                                       143                     139             2.9%            4.5%            -1.6%
WW                                                         352                     342             2.9%            3.5%            -0.6%
KNEES
US                                                         246                     244             0.8%            0.8%            -
Intl                                                       152                     145             4.8%            7.0%            -2.2%
WW                                                         398                     389             2.3%            3.1%            -0.8%
TRAUMA
US                                                         391                     381             2.6%            2.6%            -
Intl                                                       251                     261             -3.8%           -3.1%           -0.7%
WW                                                         642                     642             0.0%            0.3%            -0.3%
SPINE & OTHER
US                                                         533                     564             -5.5%           -5.5%           -
Intl                                                       400                     404             -1.0%           0.3%            -1.3%
WW                                                         933                     968             -3.6%           -3.1%           -0.5%
                                    REPORTED SALES vs. PRIOR PERIOD ($MM)
                                    FIRST QUARTER
                                                                                                   % Change
                                                           2017                    2016            Reported        Operational (1) Currency
SURGERY
US                                                         995                     981             1.4%            1.4%            -
Intl                                                       1,276                   1,247           2.3%            3.3%            -1.0%
WW                                                         2,271                   2,228           1.9%            2.5%            -0.6%
ADVANCED
US                                                         392                     352             11.4%           11.4%           -
Intl                                                       485                     464             4.5%            5.9%            -1.4%
WW                                                         877                     816             7.5%            8.3%            -0.8%
GENERAL
US                                                         423                     419             1.0%            1.0%            -
Intl                                                       651                     651             0.0%            1.2%            -1.2%
WW                                                         1,074                   1,070           0.4%            1.1%            -0.7%
SPECIALTY
US                                                         180                     210             -14.3%          -14.3%          -
Intl                                                       140                     132             6.1%            4.8%            1.3%
WW                                                         320                     342             -6.4%           -6.9%           0.5%
VISION CARE
US                                                         305                     242             26.0%           26.0%           -
Intl                                                       493                     398             23.9%           23.6%           0.3%
WW                                                         798                     640             24.7%           24.5%           0.2%
CONTACT LENSES / OTHER
US                                                         256                     242             5.8%            5.8%            -
Intl                                                       427                     398             7.3%            7.0%            0.3%
WW                                                         683                     640             6.7%            6.5%            0.2%
SURGICAL
US                                                         49                      -               **              **              -
Intl                                                       66                      -               **              **              0.0%
WW                                                         115                     -               **              **              0.0%
TOTAL MEDICAL DEVICES
US                                                         3,092                   3,026           2.2%            2.2%            -
Intl                                                       3,201                   3,083           3.8%            4.7%            -0.9%
WW                                                         $       6,293           6,109           3.0%            3.4%            -0.4%
* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-first-quarter-results-300440779.html

SOURCE Johnson & Johnson

https://rt.prnewswire.com/rt.gif?NewsItemId=NY64145&Transmission_Id=201704180640PR_NEWS_USPR_____NY64145&DateId=20170418



Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.